SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Pueblo who wrote (6374)4/12/1999 11:03:00 AM
From: Linda Kaplan  Read Replies (3) of 7041
 
Oppenheimer has reduced estimates for ZONA's 1999 income by many millions of dollars because ZONA is not on the schedule for FDA Meeting for July. That means the earliest they can be considered by the FDA Meeting Committee would be September. Assuming that Vasomax needs to be considered by that meeting committee (and Oppenheimer is assuming that) the earliest a decision would be made about approval would be after that meeting in September -- assuming they even make inclusion in the September schedule.

Linda
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News